Jade Biosciences (JBIO) stock soared 5.45% during intraday trading on Friday, following a series of positive analyst actions and outlooks for the company's pipeline.
The surge comes after Wedbush significantly raised its price target on Jade Biosciences to $34 from $24 while maintaining its Outperform rating. This represents a substantial increase of approximately 41.7% in the firm's valuation of the stock.
Additional positive sentiment stems from William Blair analyst Matt Phipps reiterating a Buy rating on the stock, citing approaching catalysts including JADE101 data and developments in the company's multi-asset pipeline. These analyst actions highlight growing optimism about Jade Biosciences' future prospects and potential value creation.